This HTML5 document contains 41 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n15http://localhost/temp/predkladatel/
n8http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n13http://linked.opendata.cz/resource/domain/vavai/subjekt/
n7http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
n10http://bibframe.org/vocab/
n12http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F61989592%3A15110%2F12%3A33140649%21RIV13-MSM-15110___/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n14http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n11http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F61989592%3A15110%2F12%3A33140649%21RIV13-MSM-15110___
rdf:type
skos:Concept n7:Vysledek
dcterms:description
Metastatic renal cell carcinoma (mRCC) is tumor resistant to all cytotoxic agents. During the last decade, effective targeted therapies emerged including sunitinib, pazopanib and the combination of bevacizumab with IFN-alfa. The use of bevacizumab plus IFN-alfa combination in mRCC is supported by the AVOREN trial. Although the primary end point of the AVOREN trial was overall survival, progression-free survival was used to evaluate efficacy and served as the basis of regulatory submission owing to the advent of targeted agents that probably resulted in the prolongation of overall survival in both experimental and control arms. The doubling of median progression-free survival in the AVOREN trials (from 5.4 to 10.2 months) is remarkably similar compared with the results of Phase III trials with sunitinib and pazopanib. Bevacizumab plus IFN-alfa is the only combined regimen currently used in mRCC and serves as a comparator in the trials combining bevacizumab with other agents. Metastatic renal cell carcinoma (mRCC) is tumor resistant to all cytotoxic agents. During the last decade, effective targeted therapies emerged including sunitinib, pazopanib and the combination of bevacizumab with IFN-alfa. The use of bevacizumab plus IFN-alfa combination in mRCC is supported by the AVOREN trial. Although the primary end point of the AVOREN trial was overall survival, progression-free survival was used to evaluate efficacy and served as the basis of regulatory submission owing to the advent of targeted agents that probably resulted in the prolongation of overall survival in both experimental and control arms. The doubling of median progression-free survival in the AVOREN trials (from 5.4 to 10.2 months) is remarkably similar compared with the results of Phase III trials with sunitinib and pazopanib. Bevacizumab plus IFN-alfa is the only combined regimen currently used in mRCC and serves as a comparator in the trials combining bevacizumab with other agents.
dcterms:title
Bevacizumab in combination with IFN-alfa in metastatic renal cell carcinoma: the AVOREN trial. Bevacizumab in combination with IFN-alfa in metastatic renal cell carcinoma: the AVOREN trial.
skos:prefLabel
Bevacizumab in combination with IFN-alfa in metastatic renal cell carcinoma: the AVOREN trial. Bevacizumab in combination with IFN-alfa in metastatic renal cell carcinoma: the AVOREN trial.
skos:notation
RIV/61989592:15110/12:33140649!RIV13-MSM-15110___
n7:predkladatel
n13:orjk%3A15110
n4:aktivita
n19:I
n4:aktivity
I
n4:cisloPeriodika
10
n4:dodaniDat
n11:2013
n4:domaciTvurceVysledku
n8:5931711 n8:3986659 n8:5290791
n4:druhVysledku
n18:J
n4:duvernostUdaju
n5:S
n4:entitaPredkladatele
n12:predkladatel
n4:idSjednocenehoVysledku
124789
n4:idVysledku
RIV/61989592:15110/12:33140649
n4:jazykVysledku
n17:eng
n4:klicovaSlova
renal cell carcinoma; bevacizumab
n4:klicoveSlovo
n14:bevacizumab n14:renal%20cell%20carcinoma
n4:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n4:kontrolniKodProRIV
[A9E595DD1D3E]
n4:nazevZdroje
Expert Review of Anticancer Therapy
n4:obor
n9:FD
n4:pocetDomacichTvurcuVysledku
3
n4:pocetTvurcuVysledku
3
n4:rokUplatneniVysledku
n11:2012
n4:svazekPeriodika
12
n4:tvurceVysledku
Melichar, Bohuslav Vitásková, Denisa Procházková, Hana
s:issn
1473-7140
s:numberOfPages
10
n10:doi
10.1586/era.12.103
n15:organizacniJednotka
15110